A new phosphospecific cell-based ELISA for p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase B and cAMP-response-element-binding protein

  • Biochem J. 2000 Sep 15;350 Pt 3(Pt 3):717-22.
H H Versteeg  1 ,  E Nijhuis ,  G R van den Brink ,  M Evertzen ,  G N Pynaert ,  S J van Deventer ,  P J Coffer ,  M P Peppelenbosch
Affiliations
  • 1. Laboratory for Experimental Internal Medicine, G2-130, Academic Medical Centre, Meibergdreef 9, NL-1105 AZ Amsterdam, The Netherlands.
PMID: 10970784
Abstract

Assaying activation of signal transduction is laborious and does not allow the study of large numbers of samples, essential for high-throughput drug screens or for large groups of patients. Using phosphospecific antibodies, we have developed ELISA techniques enabling non-radioactive semi-quantitative assessment of the activation state of p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase B and the transcription factor cAMP-response-element-binding protein (CREB) in 96-well plates. This assay has been termed PACE (phosphospecific antibody cell-based ELISA) and was used successfully for both adherent and suspension cells. Various stimuli induced dose-dependent enzymic activity of which the kinetics closely correlated with those measured via classical methodology. Using PACE we have now characterized for the first time the concentration-dependent effects of various inflammatory Prostaglandins on CREB phosphorylation in Macrophages. PACE is a straightforward and novel technique enabling the large-scale analysis of signal transduction.